RLYB Rallybio Corporation - Common Stock
$17.10
价格 · 八月 19, 2026
截至...的财报数据 八月 6, 2026
RLYB 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$17.10
市值
$90M
P/E (TTM)
-10.8
每股收益 (TTM)
$-1.59
营收 (TTM)
$858.0K
股息收益率
—
ROE
-17.3%
负债/权益
—
52周区间
$0 – $18
RLYB 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$858.0K
2024-12-31
→
2025-12-31
EPS
$-1.59
2021-12-31
→
2025-12-31
自由现金流
—
2021-12-31
→
2024-12-31
利润率
-1046.4%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
RLYB
同行中位数
P/E (TTM)
-10.8
0.8
P/S (TTM) (市销率 (TTM))
105.3
2.2
P/B (市净率)
1.6
2.3
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
RLYB
同行中位数
Operating Margin (营业利润率)
-3853.6%
—
Net Profit Margin (净利润率)
-1046.4%
-177.6%
ROA
-13.8%
-39.2%
ROE
-17.3%
-63.0%
ROIC
-57.0%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
RLYB
同行中位数
Current Ratio (流动比率)
14.5
3.9
Quick Ratio (速动比率)
13.0
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
RLYB
同行中位数
Revenue YoY (营收同比增长)
34.9%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
RLYB
同行中位数
RLYB 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
卖出
6 位分析师
- 强烈买入 0 0.0%
- 买入 0 0.0%
- 持有 3 50.0%
- 卖出 1 16.7%
- 强烈卖出 2 33.3%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.26%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年3月31日 | $-1.46 | $-1.22 | -0.24% |
| 2025年12月31日 | $-1.03 | $-1.20 | 0.17% |
| 2025年9月30日 | $-1.12 | $-1.75 | 0.63% |
| 2025年6月30日 | $-1.76 | $-2.00 | 0.24% |
| 2025年3月31日 | $-1.68 | $-2.12 | 0.44% |
| 2024年12月31日 | $-2.00 | $-2.34 | 0.34% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| RLYB | $4M | -0.4 | 34.9% | -1046.4% | -17.3% | — |
| ALDX | $312M | -9.2 | — | — | -68.0% | — |
| KLRS | $193M | -3.0 | — | — | -65.8% | — |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | — |
| ACRV | $76M | -1.2 | — | — | -61.0% | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
| GANX | $135M | -5.3 | -60.6% | — | -181.1% | — |
| ACET | — | -0.5 | — | — | — | — |
| ELTX | — | -3.1 | — | — | — | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 14
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Revenue | $858.0K | $636.0K | |
| R&D Expense | $20M | $42M | |
| SG&A Expense | $14M | $20M | |
| Operating Expenses | $34M | $61M | |
| Operating Income | $-33M | $-60M | |
| Other Non-op | $23M | $744.0K | |
| Pretax Income | $-9M | $-56M | |
| Income Tax | $0 | $0 | |
| Net Income | $-9M | $-58M | |
| EPS (Basic) | $-1.59 | $-10.61 | |
| EPS (Diluted) | $-1.59 | $-10.61 | |
| Shares (Basic) | 5,629,370 | 5,443,332 | |
| Shares (Diluted) | 5,629,370 | 5,443,332 | |
| EBITDA | $-33M | $-60M |
资产负债表 22
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $31M | $14M | |
| Short-term Investments | $23M | $52M | |
| Prepaid Expense | $7M | $2M | |
| Other Current Assets | $3M | $995.0K | |
| Current Assets | $61M | $68M | |
| PP&E (Net) | $23.0K | $115.0K | |
| PP&E (Gross) | $503.0K | $769.0K | |
| Accum. Depreciation | $480.0K | $654.0K | |
| Other Non-current Assets | $810.0K | $0 | |
| Total Assets | $62M | $68M | |
| Accounts Payable | $126.0K | $278.0K | |
| Accrued Liabilities | $4M | $5M | |
| Current Liabilities | $4M | $6M | |
| Capital Leases | $82.0K | $0 | |
| Total Liabilities | $4M | $6M | |
| Common Stock | $4.0K | $4.0K | |
| Paid-in Capital | $360M | $355M | |
| Retained Earnings | $-302M | $-293M | |
| AOCI | $18.0K | $68.0K | |
| Stockholders' Equity | $58M | $62M | |
| Liabilities + Equity | $62M | $68M | |
| Shares Outstanding | 5,283,321 | 5,188,743 |
现金流 10
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| D&A | $92.0K | $131.0K | |
| Stock-based Comp | $5M | $8M | |
| Operating Cash Flow | $-30M | $-49M | |
| CapEx | · | $0 | |
| Investing Cash Flow | $47M | $33M | |
| Stock Issued | $0 | $5M | |
| Net Stock Activity | $0 | $5M | |
| Financing Cash Flow | $16.0K | $5M | |
| Net Change in Cash | $17M | $-11M | |
| Free Cash Flow | · | $-49M |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -3853.6% | -10082.7% | |
| Net Margin | -1046.4% | -9629.2% | |
| Pretax Margin | -1046.4% | -9256.0% | |
| EBITDA Margin | -3853.6% | -10082.7% | |
| ROA | -13.8% | -62.9% | |
| ROE | -17.3% | -87.2% | |
| ROIC | -57.0% | -98.1% |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 14.5 | 10.9 | |
| Quick Ratio | 13.0 | 10.5 |
效率 1
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 |
增长率 1
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 34.9% | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $858.0K | $636.0K | |
| Net Income TTM | $-9M | $-58M | |
| Market Cap | $4M | $40M | |
| P/E | -0.4 | -0.1 | |
| P/S | 4.2 | 62.7 | |
| P/B | 0.1 | 0.6 | |
| P / Tangible Book | 0.1 | 0.6 | |
| P / Cash Flow | -0.1 | -0.8 | |
| P / FCF | · | -0.8 | |
| Earnings Yield | -231.8% | -1105.2% |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $212.0K | $222.0K | $212.0K | $212.0K | $212.0K | $38.0K | $299.0K | $299.0K | $0 | · | $0 | $0 | |
| R&D Expense | $758.0K | $3M | $4M | $4M | $6M | $6M | $7M | $8M | $13M | $13M | $16M | $13M | $13M | |
| SG&A Expense | $5M | $6M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $7M | $5M | $6M | $7M | |
| Operating Expenses | $6M | $9M | $7M | $7M | $10M | $10M | $12M | $12M | $17M | $20M | $21M | $19M | $20M | |
| Operating Income | $-6M | $-9M | $-6M | $-7M | $-10M | $-10M | $-12M | $-12M | $-17M | $-20M | $-21M | $-19M | $-20M | |
| Other Non-op | $424.0K | $254.0K | $0 | $22M | $118.0K | $174.0K | $183.0K | $251.0K | $143.0K | $167.0K | $35.0K | $92.0K | $62.0K | |
| Pretax Income | $45M | $-8M | $-7M | $16M | $-9M | $-9M | · | $-11M | $-16M | $-18M | $-20M | $-18M | $-18M | |
| Income Tax | $1M | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Net Income | $44M | $-8M | $-6M | $16M | $-10M | $-9M | $-11M | $-11M | $-16M | $-19M | $-20M | $-18M | $-19M | |
| EPS (Basic) | $7.66 | $-1.46 | $-1.52 | $0.36 | $-1.73 | $-1.69 | $-9.51 | $-0.26 | $-0.37 | $-0.47 | $-0.50 | $-0.45 | $-0.46 | |
| EPS (Diluted) | $7.53 | $-1.46 | $-1.52 | $0.36 | · | $-1.69 | $-9.51 | $-0.26 | $-0.37 | $-0.47 | $-0.50 | $-0.45 | $-0.46 | |
| Shares (Basic) | 5,699,111 | 5,688,584 | -129,044,963 | 45,058,591 | 5,605,116 | 5,597,528 | -124,051,563 | 44,593,221 | 44,128,059 | 40,773,615 | -80,696,904 | 40,531,497 | 40,363,902 | |
| Shares (Diluted) | 5,797,913 | 5,688,584 | -129,044,963 | 45,058,591 | · | 5,597,528 | -124,051,563 | 44,593,221 | 44,128,059 | 40,773,615 | -80,696,904 | 40,531,497 | 40,363,902 | |
| EBITDA | $-6M | $-9M | · | $-7M | $-10M | $-10M | · | $-12M | $-17M | $-20M | · | $-19M | $-20M |
资产负债表 22
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93M | $41M | $31M | $32M | $9M | $15M | $14M | $25M | $17M | $19M | $24M | $19M | $33M | |
| Short-term Investments | $0 | $5M | $23M | $27M | $36M | $40M | $52M | $50M | $72M | $75M | $85M | $102M | $105M | |
| Prepaid Expense | $4M | $7M | $7M | $7M | $5M | $3M | $2M | $3M | $3M | $4M | $5M | $11M | $9M | |
| Other Current Assets | $4M | $6M | $3M | $3M | $573.0K | $872.0K | $995.0K | $2M | $1M | $768.0K | $2M | $4M | $1M | |
| Current Assets | $97M | $53M | $61M | $67M | $50M | $57M | $68M | $78M | $91M | $99M | $115M | $132M | $147M | |
| PP&E (Net) | $0 | $20.0K | $23.0K | $26.0K | $61.0K | $87.0K | $115.0K | $145.0K | $177.0K | $211.0K | $246.0K | $282.0K | $308.0K | |
| PP&E (Gross) | · | · | $503.0K | · | · | · | $769.0K | · | · | · | $769.0K | · | · | |
| Accum. Depreciation | · | · | $480.0K | · | · | · | $654.0K | · | · | · | $523.0K | · | · | |
| Other Non-current Assets | $810.0K | $810.0K | $810.0K | $810.0K | · | · | $0 | · | · | · | · | · | · | |
| Total Assets | $98M | $54M | $62M | $68M | $51M | $58M | $68M | $79M | $92M | $99M | $116M | $133M | $148M | |
| Accounts Payable | $833.0K | $940.0K | $126.0K | $269.0K | $119.0K | $400.0K | $278.0K | $583.0K | $1M | $470.0K | $976.0K | $464.0K | $689.0K | |
| Accrued Liabilities | $1M | $3M | $4M | $4M | $4M | $3M | $5M | $6M | $10M | $9M | $8M | $9M | $7M | |
| Current Liabilities | $4M | $4M | $4M | $5M | $5M | $4M | $6M | $8M | $12M | $10M | $9M | $9M | $8M | |
| Capital Leases | $0 | $55.0K | $82.0K | $108.0K | · | · | $0 | $0 | $58.0K | $116.0K | $173.0K | $211.0K | $266.0K | |
| Total Liabilities | $4M | $4M | $4M | $5M | $5M | $4M | $6M | $8M | $12M | $10M | $9M | $10M | $8M | |
| Common Stock | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Paid-in Capital | $361M | $361M | $360M | $359M | $358M | $356M | $355M | $353M | $351M | $343M | $341M | $339M | $336M | |
| Retained Earnings | $-267M | $-310M | $-302M | $-296M | $-312M | $-302M | $-293M | $-282M | $-271M | $-254M | $-235M | $-215M | $-197M | |
| AOCI | $0 | $1.0K | $18.0K | $24.0K | $17.0K | $47.0K | $68.0K | $169.0K | $-71.0K | $-71.0K | $15.0K | $-208.0K | $-272.0K | |
| Stockholders' Equity | $94M | $50M | $58M | $63M | $46M | $54M | $62M | $71M | $80M | $89M | $106M | $124M | $139M | |
| Liabilities + Equity | $98M | $54M | $62M | $68M | $51M | $58M | $68M | $79M | $92M | $99M | $116M | $133M | $148M | |
| Shares Outstanding | 5,306,894 | 5,290,236 | 5,283,321 | 41,935,841 | 41,707,153 | 41,612,039 | 5,188,743 | 41,487,586 | 41,487,586 | 37,811,970 | 37,829,565 | 37,800,856 | 37,790,856 |
现金流 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.0K | $3.0K | $3.0K | $35.0K | $26.0K | $28.0K | $30.0K | $32.0K | $34.0K | $35.0K | $36.0K | $37.0K | $38.0K | |
| Stock-based Comp | $424.0K | $613.0K | $774.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | |
| Operating Cash Flow | $46M | $-8M | $-5M | $-7M | $-8M | $-10M | $-10M | $-14M | $-10M | $-15M | $-12M | $-16M | $-13M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | $12.0K | $0 | $0 | |
| Investing Cash Flow | $6M | $18M | $4M | $29M | $3M | $11M | $-2M | $22M | $3M | $10M | $17M | $3M | $6M | |
| Stock Issued | · | $3.0K | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | $-209.0K | · | |
| Net Stock Activity | · | $3.0K | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $131.0K | $3.0K | $6.0K | $0 | $10.0K | $0 | $18.0K | $-11.0K | $5M | $0 | $72.0K | $0 | $210.0K | |
| Net Change in Cash | $52M | $10M | $-748.0K | $23M | $-5M | $876.0K | $-11M | $9M | $-3M | $-5M | $5M | $-13M | $-7M |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -4119.3% | · | -3266.5% | -4743.9% | -4561.3% | · | -4035.5% | -5697.3% | · | · | · | · | |
| Net Margin | · | -3904.7% | · | 7554.7% | -4576.9% | -4452.4% | · | -3834.8% | -5430.1% | · | · | · | · | |
| Pretax Margin | · | -3904.7% | · | 7554.7% | -4441.5% | -4175.5% | · | -3621.7% | -5267.2% | · | · | · | · | |
| EBITDA Margin | · | -4119.3% | · | -3266.5% | -4743.9% | -4561.3% | · | -4035.5% | -5697.3% | · | · | · | · | |
| ROA | 58.6% | -14.7% | · | 21.8% | -13.5% | -12.0% | · | -10.8% | -13.5% | -14.5% | · | -13.3% | -12.3% | |
| ROE | 62.2% | -15.9% | · | 23.9% | -15.4% | -13.2% | · | -11.8% | -14.8% | -15.6% | · | -14.4% | -13.0% | |
| ROIC | -5.8% | · | · | · | · | · | · | · | · | · | · | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 27.3 | 12.9 | · | 14.7 | 10.0 | 14.7 | · | 9.6 | 7.5 | 9.8 | · | 14.1 | 18.2 | |
| Quick Ratio | 26.0 | 11.3 | · | 13.1 | 9.1 | 13.9 | · | 9.2 | 7.3 | 9.3 | · | 12.9 | 17.1 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | · |
估值 (TTM) 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $636.0K | $848.0K | · | $935.0K | $1M | $810.0K | · | $598.0K | $299.0K | · | · | · | · | |
| Net Income TTM | $42M | $-11M | · | $-15M | $-47M | $-56M | · | $-65M | $-72M | $-73M | · | $-73M | $-72M | |
| Market Cap | $85M | $47M | · | $21M | $14M | $27M | · | $49M | $56M | $70M | · | $127M | $214M | |
| P/E | · | -3.0 | · | -1.5 | -0.3 | -0.5 | · | -0.8 | -0.8 | -1.0 | · | -1.7 | -2.7 | |
| P/S | 133.5 | 56.0 | · | 22.4 | 13.8 | 33.6 | · | 81.2 | 185.9 | · | · | · | · | |
| P/B | 0.9 | 0.9 | · | 0.3 | 0.3 | 0.5 | · | 0.7 | 0.7 | 0.8 | · | 1.0 | 1.5 | |
| P / Tangible Book | 0.9 | 0.9 | · | 0.3 | 0.3 | 0.5 | · | 0.7 | 0.7 | 0.8 | · | 1.0 | 1.5 | |
| P / Cash Flow | · | -5.9 | · | · | · | -2.7 | · | · | · | -4.5 | · | · | · | |
| Earnings Yield | · | -33.6% | · | -66.1% | -313.6% | -200.0% | · | -132.5% | -130.6% | -97.8% | · | -57.6% | -36.4% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $858.0K | $636.0K | — | — | — |
| 营业利润率 % | -3853.6% | -10082.7% | — | — | — |
| 净收入 | $-9M | $-58M | $-75M | $-67M | $-47M |
| 稀释后每股收益 (EPS) | $-1.59 | $-10.61 | $-1.84 | $-2.09 | $-1.84 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 14.5 | 10.9 | 12.4 | 16.7 | 27.6 |
| 速动比率 | 13.0 | 10.5 | 11.9 | 15.7 | 26.8 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | — | $-49M | $-60M | $-57M | $-46M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 42 家申报者 · $69.2M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 13 | 9 | 7 | 6 | — |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。 与上一季度变动未显示：在此两个季度之间，申报方覆盖范围差异过大，无法进行可靠的比较。
公司内部人士 15 位内幕人士 · 5 位高管 · 10 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Martin Mackay | Chief Executive Officer | 2023年2月6日 A | 282609 | 0 | 0 | $0 |
| Jonathan I Lieber | Chief Financial Officer and Treasurer | 2023年3月14日 P | 5000 | 0 | 0 | $0 |
| Jeffrey M Fryer | Chief Financial Officer & Treasurer | 2022年3月21日 P | 47048 | 0 | 0 | $0 |
| Stephen Uden | Chief Operating Officer & Chief Scientific Officer | 2023年2月6日 A | 719127 | 0 | 0 | $0 |
| Steven Ryder | Chief Medical Officer | 2023年2月6日 A | — | 0 | 0 | $0 |
| Wendy Chung | 董事 | 2023年5月17日 A | — | 0 | 0 | $0 |
| Hui Liu | 董事 | 2023年5月17日 A | — | 0 | 0 | $0 |
| Paula Soteropoulos | 董事 | 2023年5月17日 A | — | 0 | 0 | $0 |
| Kush Parmar | 董事 | 2023年5月17日 A | 2378969 | 0 | 0 | $0 |
| Helen M Boudreau | 董事 | 2023年5月17日 A | — | 0 | 0 | $0 |
| Christine A Nash | 董事 | 2023年5月17日 A | — | 0 | 0 | $0 |
| Robert Lorne Hopfner | 董事 | 2023年5月17日 A | 2267411 | 0 | 0 | $0 |
| Ronald Hunt | 董事 | 2023年5月17日 A | 2301603 | 0 | 0 | $0 |
| Timothy M Shannon | 董事 | 2022年1月3日 A | 2409712 | 0 | 0 | $0 |
| FMR LLC | — | 2021年8月2日 C | 1694388 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 5 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Andrew J. Schwab, Kush Parmar, Scott M. Rocklage ×2 申报 | 2026年5月6日 | 0.00% | 修订 | — | SEC |
| TPG GP A, LLC, James G. Coulter, Jon Winkelried ×2 申报 | 2026年3月3日 | 7.20% | 修订 | 并购/出售 | SEC |
| Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P. Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited ×2 申报 | 2024年2月12日 | — | 初始申报 | — | SEC |
| 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Andrew J. Schwab, Dr. Kush Parmar, Dr. Scott M. Rocklage ×2 申报 | 2022年6月7日 | — | 初始申报 | — | SEC |
| TPG Group Holdings (SBS) Advisors, Inc., David Bonderman, James G. Coulter | 2021年8月12日 | — | 初始申报 | 资本结构 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 4 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。